

# **CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***

**22-304**

**LABELING**

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use **TRADENAME™** safely and effectively. See full prescribing information for **TRADENAME™**.

**TRADENAME™ (tapentadol) immediate release oral tablets**  
Initial U.S. Approval : 2008

### INDICATIONS AND USAGE

**TRADENAME™** is an opioid analgesic indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. (1)

### DOSAGE AND ADMINISTRATION

- As with many centrally-acting analgesic medications, the dosing regimen of **TRADENAME™** should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient. (2)
- Initiate **TRADENAME™** with or without food at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended. (2)

### DOSAGE FORMS AND STRENGTHS

Tablets: 50 mg, 75 mg, 100 mg (3)

### CONTRAINDICATIONS

- Impaired pulmonary function (significant respiratory depression, acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment) (4.1)
- Paralytic ileus (4.2)
- Concomitant use with monoamine oxidase inhibitors (MAOI) or use within 14 days (4.3)

### WARNINGS AND PRECAUTIONS

- Respiratory depression: Increased risk in elderly, debilitated patients, those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction. (5.1)
- CNS effects: Additive CNS depressive effects when used in conjunction with alcohol, other opioids, or illicit drugs. (5.2)
- Elevation of intracranial pressure: May be markedly exaggerated in the presence of head injury, other intracranial lesions. (5.3)

- Abuse potential may occur. Monitor patients closely for signs of abuse and addiction. (5.4)
- Impaired mental/physical abilities: Caution must be used with potentially hazardous activities. (5.5)
- Seizures: Use with caution in patients with a history of seizures. (5.7)
- Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic administration. (5.8)

### ADVERSE REACTIONS

The most common adverse events were nausea, dizziness, vomiting and somnolence. (6)

To report SUSPECTED ADVERSE REACTIONS, contact **PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.** at 1-800-526-7736 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### DRUG INTERACTIONS

- Use **TRADENAME™** with caution in patients currently using specified centrally-acting drugs or alcohol. (7.3)
- Do not use **TRADENAME™** in patients currently using or within 14 days of using a monoamine oxidase inhibitor (MAOI). (7.4)

### USE IN SPECIFIC POPULATIONS

- Labor and delivery: should not use during and immediately prior to labor and delivery. Monitor neonates, whose mothers have been taking **TRADENAME™**, for respiratory depression. (8.2)
- Nursing mothers: should not breast-feed. (8.3)
- Pediatric use: safety and effectiveness not established in patients less than 18 years of age. (8.4)
- Renal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in patients with moderate hepatic impairment. (8.6, 8.7)
- Elderly: care should be taken when selecting an initial dose. (2.3)

See 17 for PATIENT COUNSELING INFORMATION AND MEDICATION GUIDE.

Revised: 11/2008

# FULL PRESCRIBING INFORMATION: CONTENTS\*

<b>1</b>	<b>INDICATIONS AND USAGE</b>	8.2	Labor and Delivery
<b>2</b>	<b>DOSAGE AND ADMINISTRATION</b>	8.3	Nursing Mothers
2.1	Renal Impairment	8.4	Pediatric Use
2.2	Hepatic Impairment	8.5	Geriatric Use
2.3	Elderly Patients	8.6	Renal Impairment
<b>3</b>	<b>DOSAGE FORMS AND STRENGTHS</b>	8.7	Hepatic Impairment
<b>4</b>	<b>CONTRAINDICATIONS</b>	<b>9</b>	<b>DRUG ABUSE AND DEPENDENCE</b>
4.1	Impaired Pulmonary Function	9.1	Controlled Substance
4.2	Paralytic Ileus	9.2	Abuse
4.3	Monoamine Oxidase Inhibitors	9.3	Dependence
<b>5</b>	<b>WARNINGS AND PRECAUTIONS</b>	<b>10</b>	<b>OVERDOSAGE</b>
5.1	Respiratory Depression	10.1	Human Experience
5.2	CNS Depression	10.2	Management of Overdose
5.3	Head Injury and Increased Intracranial Pressure	<b>11</b>	<b>DESCRIPTION</b>
5.4	Misuse and Abuse	<b>12</b>	<b>CLINICAL PHARMACOLOGY</b>
5.5	Driving and Operating Machinery	12.1	Mechanism of Action
5.6	Interactions with Alcohol and Drugs of Abuse	12.2	Pharmacodynamics
5.7	Seizures	12.3	Pharmacokinetics
5.8	Serotonin Syndrome Risk	<b>13</b>	<b>NON-CLINICAL TOXICOLOGY</b>
5.9	Withdrawal	13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
5.10	Hepatic Impairment	13.2	Animal Toxicology and/or Pharmacology
5.11	Use in Pancreatic/Biliary Tract Disease	<b>14</b>	<b>CLINICAL STUDIES</b>
<b>6</b>	<b>ADVERSE REACTIONS</b>	14.1	<b>Orthopedic Surgery – Bunionectomy</b>
6.1	Commonly-Observed Treatment-Emergent Adverse Events in Double-Blind Controlled Clinical Trials	14.2	End-Stage Degenerative Joint Disease
6.2	Other Adverse Reactions Observed During the Premarketing Evaluation of TRADENAME™	<b>16</b>	<b>HOW SUPPLIED/STORAGE AND HANDLING</b>
<b>7</b>	<b>DRUG INTERACTIONS</b>	<b>17</b>	<b>PATIENT COUNSELING INFORMATION</b>
7.1	Drugs Metabolized by Cytochrome P450 Enzymes	17.1	Instructions for Use
7.2	Drugs That Inhibit or Induce Cytochrome P450 Enzymes	17.2	Misuse and Abuse
7.3	Centrally-Acting Drugs and Alcohol	17.3	Interference with Cognitive and Motor Performance
7.4	Monoamine Oxidase Inhibitors	17.4	Pregnancy
<b>8</b>	<b>USE IN SPECIFIC POPULATIONS</b>	17.5	Nursing
8.1	Pregnancy	17.6	Monoamine Oxidase Inhibitors
		17.7	Seizures
		17.8	Serotonin Syndrome
		17.9	Alcohol
		7.10	Medication Guide

[\*Sections or  
subsections omitted from the full prescribing information are not listed]

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

TRADENAME™ is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older.

### 2 DOSAGE AND ADMINISTRATION

As with many centrally-acting analgesic medications, the dosing regimen should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient.

The dose is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity.

On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.

Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.

TRADENAME™ may be given with or without food [*see Clinical Pharmacology (12.3)*].

#### 2.1 Renal Impairment

No dosage adjustment is recommended in patients with mild or moderate renal impairment [*see Clinical Pharmacology (12.3)*].

TRADENAME™ has not been studied in patients with severe renal impairment. The use in this population is not recommended.

#### 2.2 Hepatic Impairment

No dosage adjustment is recommended in patients with mild hepatic impairment [*see Clinical Pharmacology (12.3)*].

TRADENAME™ should be used with caution in patients with moderate hepatic impairment. Treatment in these patients should be initiated at 50 mg with the interval between doses no less than every 8 hours (maximum of three doses in 24 hours). Further treatment should reflect maintenance of analgesia with acceptable tolerability, to be achieved by either shortening or lengthening the dosing interval [*see Clinical Pharmacology (12.3)*].

TRADENAME™ has not been studied in patients with severe hepatic impairment and use in this population is not recommended [*see Warnings and Precautions (5.10)*].

### 2.3 Elderly Patients

In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses.

## 3 DOSAGE FORMS AND STRENGTHS

TRADENAME™ Tablets are round, biconvex and film-coated and are available in the following strengths, colors, and debossings: 50 mg of tapentadol (yellow with “O-M” on one side and “50” on the other side), 75 mg of tapentadol (yellow-orange with “O-M” on one side and “75” on the other side), and 100 mg of tapentadol (orange with “O-M” on one side and “100” on the other side).

## 4 CONTRAINDICATIONS

### 4.1 Impaired Pulmonary Function

Like other drugs with mu-opioid agonist activity, TRADENAME™ is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. TRADENAME™ is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [*see Warnings and Precautions (5.1)*].

### 4.2 Paralytic Ileus

Like drugs with mu-opioid agonist activity, TRADENAME™ is contraindicated in any patient who has or is suspected of having paralytic ileus.

### 4.3 Monoamine Oxidase Inhibitors

TRADENAME™ is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [*see Drug Interactions (7.4)*].

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Respiratory Depression

Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.

TRADENAME™ should be administered with caution to patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of TRADENAME™ may increase airway resistance and decrease respiratory

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.